Botulinum toxin injection into the intrinsic laryngeal muscles to treat spasmodic dysphonia: A multicenter, placebo‐controlled, randomized, double‐blinded, parallel‐group comparison/open‐label clinical trial
Authors:
Open Access
- 4 January 2021
- journal article
- research article
- Published by Wiley in European Journal of Neurology
- Vol. 28 (5) , 1548-1556
Abstract
Background and purpose: Botulinum toxin (BT) injection into the laryngeal muscles has been a standard treatment for spasmodic dysphonia (SD). However, few high‐quality clinical studies have appeared, and BT is used off‐label in most countries.Methods: We performed a multicenter, placebo‐controlled, randomized, double‐blinded, parallel‐group comparison/open‐label clinical trial to obtain approval for BT (Botox) therapy in Japan. Twenty‐four patients (22 with adductor SD and two with abductor SD) were enrolled. The primary end point was the change in the number of aberrant morae (phonemes) at 4 weeks after drug injection. The secondary end points included the change in the number of aberrant morae, GRBAS scale, Voice Handicap Index (VHI), and visual analog scale (VAS) over the entire study period.Results: In the adductor SD group, the number of aberrant morae at 4 weeks after injection was reduced by 7.0 ± 2.30 (mean ± SE) in the BT group and 0.2 ± 0.46 in the placebo group (p = 0.0148). The improvement persisted for 12 weeks following BT injections. The strain element in GRBAS scale significantly reduced at 2 weeks after BT treatment. The VHI and VAS scores as subjective parameters also improved. In the abductor SD group, one patient responded to treatment. Adverse events included breathy hoarseness (77.3%) and aspiration when drinking (40.9%) but were mild and resolved in 4 weeks.Conclusions: Botulinum toxin injection was safe and efficacious for the treatment of SD. Based on these results, BT injection therapy was approved as an SD treatment in Japan.Keywords
This publication has 31 references indexed in Scilit:
- Spasmodic dysphonia and botulinum toxin: experience from the largest treatment seriesEuropean Journal of Neurology, 2010
- Treatment for spasmodic dysphonia: limitations of current approachesCurrent Opinion in Otolaryngology & Head and Neck Surgery, 2009
- Surgical treatment for adductor spasmodic dysphonia – efficacy of bilateral thyroarytenoid myectomy under microlaryngoscopyActa Oto-Laryngologica, 2008
- Botulinum toxin injections for the treatment of spasmodic dysphoniaCochrane Database of Systematic Reviews, 2004
- A Comparison of Voice Quality Ratings Made by Japanese and American Listeners Using the GRBAS ScaleFolia Phoniatrica et Logopaedica, 2003
- Thyroplasty for Adductor Spasmodic Dysphonia: Further ExperiencesThe Laryngoscope, 2001
- Japanese Mora-Timing: A ReviewPhonetica, 2000
- Double‐blind controlled study of botulinum toxin in adductor spasmodic dysphoniaThe Laryngoscope, 1991
- Clinical and laboratory characteristics of focal laryngeal dystonia: Study of 110 casesThe Laryngoscope, 1988
- Intermediate results of 306 recurrent laryngeal nerve sections for spastic dysphoniaThe Laryngoscope, 1983